Neonc Technologies Holdings
Neonc Technologies Holdings' revenue fell 51.8% to $0 million in fiscal 2025. Its operating margin was −145,637.5%, down from −8,605.5% a year earlier. Free cash flow was −$21 million. The diluted share count rose 11.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Neonc Technologies Holdings lost money in fiscal 2025: a net loss of $62 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | 0 | 0 |
| Debt incl. finance leases | — | — |
| Net debt (negative means net cash) | — | — |
| Net debt to EBITDA | — | — |
| Debt to equity | — | — |
| Interest coverage | −2.8x | −23.2x |
| Current ratio | 0.2x | 0.1x |
| Quick ratio | 0.2x | 0.1x |
Cash flow
Projections
Project Neonc Technologies Holdings' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $1.3 million of Neonc Technologies Holdings shares on the open market, and 1 insider sold $16,800, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Amir F HeshmatpourCEO, President, Director, 10% owner | Bought | 35,000 | $3.30 | $115,500 | Form 4 |
| Sep 15, 2026 | Keithly GarnettCFO | Sold plan | 5,000 | $3.36 | $16,800 | Form 4 |
| Sep 14, 2026 | Amir F HeshmatpourCEO, President, Director, 10% owner | Bought | 15,000 | $3.96 | $59,400 | Form 4 |
| Sep 14, 2026 | Thomas C ChenCEO, Director, 10% owner | Bought | 5,242 | $3.82 | $20,024 | Form 4 |
| Sep 14, 2026 | Keithly GarnettCFO | Bought | 257 | $3.89 | $1,000 | Form 4 |
| Sep 11, 2026 | Amir F HeshmatpourCEO, President, Director, 10% owner | Bought | 37,000 | $3.67 | $135,790 | Form 4 |
| Sep 11, 2026 | Thomas C ChenCEO, Director, 10% owner | Bought | 5,556 | $3.60 | $20,002 | Form 4 |
| Aug 18, 2026 | Thomas C ChenCEO, Director, 10% owner | Bought | 12,757 | $5.49 | $70,036 | Form 4 |
| Aug 18, 2026 | Amir F HeshmatpourCEO, President, Director, 10% owner | Bought | 9,000 | $5.54 | $49,860 | Form 4 |
| Aug 17, 2026 | Amir F HeshmatpourCEO, President, Director, 10% owner | Bought | 3,000 | $4.37 | $13,110 | Form 4 |
| Aug 17, 2026 | Thomas C ChenCEO, Director, 10% owner | Bought | 2,472 | $4.04 | $9,987 | Form 4 |
| Aug 14, 2026 | Thomas C ChenCEO, Director, 10% owner | Bought | 33,787 | $3.85 | $130,080 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | −52,224.7% |
| Altman Z'' | −313.02 |
| Accruals ratio | −1,339.0% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Fail |
| Cash from operations is positive | Fail |
| Return on assets rose | — |
| Cash from operations exceeds net income | Pass |
| Debt fell relative to assets | — |
| Current ratio rose | Fail |
| Share count didn't rise | Fail |
| Gross margin rose | — |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put Neonc Technologies Holdings side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Neonc Technologies Holdings | FY25 | −51.8% | −145,637.5% | −52,172.9% | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | 0 | 0 |
| Revenue growth | — | −51.8% |
| Gross profit | — | — |
| Research and development | 3 | 4 |
| Operating income | −7 | −58 |
| Net income | −12 | −62 |
| Diluted EPS (US$) | −0.69 | −3.20 |
| Diluted shares (millions) | 17 | 19 |
| Cash flow | ||
| Cash from operations | −4 | −20 |
| Capital expenditure | — | 0 |
| Free cash flow | — | −21 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | — | 36 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | 0 | 0 |
| Debt incl. finance leases | — | — |
| Total assets | 3 | 3 |
| Total liabilities | 9 | 20 |
| Shareholders' equity | −6 | −18 |
| Margins and ratios | ||
| Gross margin | — | — |
| Operating margin | −8,605.5% | −145,637.5% |
| Net margin | −14,335.5% | −155,404.4% |
| Free cash flow margin | — | −52,172.9% |
| Rule of 40 (growth + FCF margin) | — | −52,224.7% |
| Return on capital | — | — |
| Return on equity | — | — |
| Return on assets | — | −1,991.6% |
| Net debt to EBITDA | — | — |